Equities Analysts Issue Forecasts for Synthorx Inc’s Q1 2019 Earnings (THOR)
Synthorx Inc (NASDAQ:THOR) – Jefferies Financial Group issued their Q1 2019 earnings per share estimates for Synthorx in a research report issued on Wednesday, March 13th. Jefferies Financial Group analyst B. Amin forecasts that the medical instruments supplier will post earnings per share of ($0.33) for the quarter. Jefferies Financial Group has a “Buy” rating and a $21.00 price objective on the stock. Jefferies Financial Group also issued estimates for Synthorx’s Q2 2019 earnings at ($0.39) EPS, Q3 2019 earnings at ($0.45) EPS, Q4 2019 earnings at ($0.55) EPS, FY2019 earnings at ($1.52) EPS, FY2020 earnings at ($2.94) EPS, FY2021 earnings at ($2.99) EPS, FY2022 earnings at ($2.98) EPS and FY2023 earnings at ($3.53) EPS.
Separately, HC Wainwright assumed coverage on shares of Synthorx in a research report on Wednesday, January 2nd. They set a “buy” rating and a $30.00 price target for the company.
Synthorx (NASDAQ:THOR) last released its quarterly earnings results on Tuesday, March 12th. The medical instruments supplier reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.77).
A number of hedge funds have recently added to or reduced their stakes in the business. Monashee Investment Management LLC purchased a new stake in shares of Synthorx in the 4th quarter valued at approximately $435,000. Dean Capital Investments Management LLC purchased a new stake in shares of Synthorx in the 4th quarter valued at approximately $827,000. Matisse Capital purchased a new stake in shares of Synthorx in the 4th quarter valued at approximately $956,000. FMR LLC purchased a new stake in shares of Synthorx in the 4th quarter valued at approximately $38,559,000. Finally, Orbimed Advisors LLC purchased a new stake in shares of Synthorx in the 4th quarter valued at approximately $92,398,000. Institutional investors own 75.85% of the company’s stock.
Synthorx, Inc, a biotechnology company, discovers and develops protein therapeutics. The company's lead product candidate is THOR-707, a variant of IL-2 that is in development in various tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company was founded in 2014 and is headquartered in La Jolla, California.
Featured Story: Options Trading
Receive News & Ratings for Synthorx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthorx and related companies with MarketBeat.com's FREE daily email newsletter.